Weight loss drug maker sinks 25% after new safety data spooks investors: While the experimental drug met its key targets, analysts are concerned over the commercial opportunity due to side effects. #WeightLoss #Pharmaceuticals #Investing #HealthNews #SafetyData
Discover more from umlegacypress
Subscribe to get the latest posts sent to your email.
Leave a Reply